- Home
- FIGS vs TSHA Comparison
FIGS vs TSHA Comparison
Compare FIGS & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIGS
- TSHA
- Stock Information
- Founded
- FIGS 2013
- TSHA 2019
- Country
- FIGS United States
- TSHA United States
- Employees
- FIGS N/A
- TSHA N/A
- Industry
- FIGS Apparel
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- FIGS Consumer Discretionary
- TSHA Health Care
- Exchange
- FIGS Nasdaq
- TSHA Nasdaq
- Market Cap
- FIGS 694.0M
- TSHA 728.4M
- IPO Year
- FIGS 2021
- TSHA 2020
- Fundamental
- Price
- FIGS $5.25
- TSHA $2.46
- Analyst Decision
- FIGS Sell
- TSHA Strong Buy
- Analyst Count
- FIGS 4
- TSHA 7
- Target Price
- FIGS $4.50
- TSHA $7.57
- AVG Volume (30 Days)
- FIGS 1.6M
- TSHA 4.9M
- Earning Date
- FIGS 08-07-2025
- TSHA 08-11-2025
- Dividend Yield
- FIGS N/A
- TSHA N/A
- EPS Growth
- FIGS N/A
- TSHA N/A
- EPS
- FIGS 0.01
- TSHA N/A
- Revenue
- FIGS $561,166,000.00
- TSHA $7,224,000.00
- Revenue This Year
- FIGS $0.72
- TSHA N/A
- Revenue Next Year
- FIGS $2.97
- TSHA N/A
- P/E Ratio
- FIGS $731.00
- TSHA N/A
- Revenue Growth
- FIGS 3.02
- TSHA N/A
- 52 Week Low
- FIGS $3.57
- TSHA $1.05
- 52 Week High
- FIGS $7.06
- TSHA $3.31
- Technical
- Relative Strength Index (RSI)
- FIGS 64.50
- TSHA 45.90
- Support Level
- FIGS $4.98
- TSHA $2.48
- Resistance Level
- FIGS $5.16
- TSHA $2.66
- Average True Range (ATR)
- FIGS 0.22
- TSHA 0.21
- MACD
- FIGS 0.03
- TSHA -0.06
- Stochastic Oscillator
- FIGS 84.03
- TSHA 10.14
About FIGS FIGS Inc.
FIGS Inc is a healthcare apparel company. The Company designs and sells scrubwear and non-scrubwear, such as outerwear, underscrubs, footwear, compression socks, lab coats, loungewear and other apparel. The Company generates maximum revenue from United States. Sales are generated through the Company's digital platforms.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.